Omrix Biopharmaceuticals Overview

  • Founded
  • 1995
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 8
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $458M
Latest Deal Amount
  • Investors
  • 1

Omrix Biopharmaceuticals General Information

Description

Developer and manufacturer of products derived from human plasma. The company develops hemostatic products designed to control bleeding during surgery and immunotherapy products for the treatment of patients with immune deficiencies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Devices and Supplies
Primary Office
  • One Rockefeller Center
  • Suite 2322
  • New York, NY 10020
  • United States
+1 (212) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Omrix Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 30-Dec-2008 $458M 000.00 00000 Completed Clinical Trials - Phase 3
8. IPO 21-Apr-2006 000.00 000.00 00000 Completed Clinical Trials - Phase 3
7. Mezzanine 01-Apr-2005 00.000 000.00 Completed Clinical Trials - Phase 3
6. Debt - General 01-Mar-2005 000 000.00 Completed Clinical Trials - Phase 3
5. Secondary Transaction - Private 01-Feb-2005 00.00 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B) 05-Aug-2004 00.00 000.00 000.00 Completed Product Development
3. Later Stage VC (Series A) 22-Mar-2001 000 000.00 000.00 Completed Product Development
2. Early Stage VC 04-Sep-1999 $20M $35.2M Completed Product Development
1. Early Stage VC 01-Jan-1998 $15.2M $15.2M Completed Product Development
To view Omrix Biopharmaceuticals’s complete valuation and funding history, request access »

Omrix Biopharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A 000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Omrix Biopharmaceuticals’s complete cap table history, request access »

Omrix Biopharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Robert Taub Founder, President, Board Member & Chief Executive Officer
To view Omrix Biopharmaceuticals’s complete executive team members history, request access »

Omrix Biopharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Omrix Biopharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AlpInvest Partners PE/Buyout Minority 000 0000 000000 0
BRM Group Venture Capital Minority 000 0000 000000 0
Capricorn Partners Venture Capital Minority 000 0000 000000 0
Catalyst Investments Growth/Expansion Minority 000 0000 000000 0
Catalyst Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »